The widespread application of organ transplantation to the large population of patients with end-stage organ failure who are in dire need of its benefits is currently being hampered by a number of challenges. Amongst them are the shortage of organs for transplantation and the need for life-long immunosuppression with the associated untoward side effects. The field of regenerative medicine is rapidly evolving, thus creating exciting opportunities toward the development of novel therapeutic protocols aimed at ameliorating, reducing, modifying, correcting and curing medical conditions. Mesenchymal stromal (stem) cells (MSC) are appealing for inclusion in organ transplantation protocols because of the increasing body of evidence in support of their beneficial properties both in tissue repair and for the modulation of immunity. We will review the encouraging results of the recent clinical trials on the use of MSC to improve organ transplantation outcomes.